Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

584 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Remote Monitoring and Data Collection for Decentralized Clinical Trials.
Daly B, Brawley OW, Gospodarowicz MK, Olopade OI, Fashoyin-Aje L, Smart VW, Chang IF, Tendler CL, Kim G, Fuchs CS, Beg MS, Zhang L, Legos JJ, Duran CO, Kalidas C, Qian J, Finnegan J, Pilarski P, Keane H, Shen J, Silverstein A, Wu YL, Pazdur R, Li BT. Daly B, et al. Among authors: pazdur r. JAMA Netw Open. 2024 Apr 1;7(4):e246228. doi: 10.1001/jamanetworkopen.2024.6228. JAMA Netw Open. 2024. PMID: 38607626 Free PMC article.
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
Pinato DJ, Li X, Mishra-Kalyani P, D'Alessio A, Fulgenzi CAM, Scheiner B, Pinter M, Wei G, Schneider J, Rivera DR, Pazdur R, Theoret MR, Casak S, Lemery S, Fashoyin-Aje L, Cortellini A, Pelosof L. Pinato DJ, et al. Among authors: pazdur r. JHEP Rep. 2023 Mar 30;5(6):100747. doi: 10.1016/j.jhepr.2023.100747. eCollection 2023 Jun. JHEP Rep. 2023. PMID: 37197442 Free PMC article.
A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.
Lee D, Gittleman H, Weinstock C, Suzman D, Bloomquist E, Agrawal S, Brave M, Brewer J, Fallah J, Singh H, Tang S, Ibrahim A, Pazdur R, Beaver JA, Amiri-Kordestani L. Lee D, et al. Among authors: pazdur r. Eur Urol. 2023 Oct;84(4):373-378. doi: 10.1016/j.eururo.2023.05.030. Epub 2023 Jun 2. Eur Urol. 2023. PMID: 37271635
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
Fusco MJ, Casak SJ, Mushti SL, Cheng J, Christmas BJ, Thompson MD, Fu W, Wang H, Yoon M, Yang Y, Moore JN, Bi Y, Nan Y, Long CE, Auth D, Rahman NA, Tang S, Pazdur R, Fashoyin-Aje LA, Kluetz PG, Lemery SJ. Fusco MJ, et al. Among authors: pazdur r. Clin Cancer Res. 2024 May 29. doi: 10.1158/1078-0432.CCR-24-0281. Online ahead of print. Clin Cancer Res. 2024. PMID: 38809262
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
Fallah J, Xu J, Weinstock C, Gao X, Heiss BL, Maguire WF, Chang E, Agrawal S, Tang S, Amiri-Kordestani L, Pazdur R, Kluetz PG, Suzman DL. Fallah J, et al. Among authors: pazdur r. J Clin Oncol. 2024 May 10;42(14):1687-1698. doi: 10.1200/JCO.23.02105. Epub 2024 Mar 14. J Clin Oncol. 2024. PMID: 38484203
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
Heiss BL, Chang E, Gao X, Truong T, Brave MH, Bloomquist E, Shah A, Hamed S, Kraft J, Chiu HJ, Ricks TK, Tilley A, Pierce WF, Tang L, Abukhdeir A, Kalavar S, Philip R, Tang S, Pazdur R, Amiri-Kordestani L, Kluetz PG, Suzman DL. Heiss BL, et al. Among authors: pazdur r. J Clin Oncol. 2024 May 20;42(15):1851-1860. doi: 10.1200/JCO.23.02182. Epub 2024 Mar 7. J Clin Oncol. 2024. PMID: 38452327 Clinical Trial.
584 results